Evidence map›Paper›PMID 41362730›Full record

ArticleInternational journal of biological sciences2026

Pan-cancer bone metastasis atlas at single-cell resolution identifies a distinct tumor-associated macrophage subset for mediating Denosumab-induced immunosensitization in lung cancer bone metastasis.

Xianglin Hu, Nan Du, Yansha Song, Ke Lang, Wanning Tong, Qingrong Ye, Xuesi Liu, Haoyu Zheng, Mo Cheng, Yingzheng Ji and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Xianglin HuDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Nan DuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yansha SongDepartment of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Ke LangDepartment of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Wanning TongDepartment of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Naval Medical University, Shanghai, China.
Qingrong YeDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xuesi LiuDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Haoyu ZhengDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Mo ChengDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yingzheng JiDepartment of Orthopedics, Naval Medical Center of People's Liberation Army, Naval Medical University, Shanghai, China.
Haibo WuDepartment of Thoracic Surgery, Naval Medical Center of People's Liberation Army, Naval Medical University, Shanghai, China.
Minghe ZhangDepartment of Thoracic Surgery, Naval Medical Center of People's Liberation Army, Naval Medical University, Shanghai, China.
Xinhong HeDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yan ZhangDepartment of Orthopedics, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.
Xiaomeng LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yao ZhuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Kun LiHealth Science Center, East China Normal University, Shanghai, China.
Weiluo CaiDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Wangjun YanDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Wending HuangDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer (LC), prostate cancer (PC), and breast cancer (BC) are the three most prevalent cancers that lead to bone metastasis (BoM). In this study, we conducted an integrated analysis of single-cell transcriptomic data from the primary tumors and BoM across PC, LC, and BC. We discover a novel subtype of tumor-associated macrophages (TAMs) that are positive both for matrix metalloproteinase 19 (MMP19) and receptor activator of nuclear factor-κB (RANK) expression (MMP19

Indexed as

Bone NeoplasmsDenosumabLung NeoplasmsAnimalsFemaleHumansMatrix Metalloproteinases, SecretedMiceMice, Inbred C57BLNF-kappa BProstatic NeoplasmsTumor-Associated MacrophagesDenosumabmatrix metalloproteinase 19Matrix Metalloproteinases, SecretedNF-kappa Bbone metastasisDenosumabRANKLsingle-cell sequencingtumor-associated macrophages

Identifiers

PMID41362730
PMCPMC12681936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.